Skip to main content

Table 2 Medicine use per dataset to Anatomical Chemical Therapeutic level 2

From: Determining antenatal medicine exposures in South African women: a comparison of three methods of ascertainment

Total = 967

 

EDR

EDR %

Clinician record

Clinician record %

Self-report

Self-report %

aMaster List

aMaster List %

none

434

44.88%

133

13.75%

20

2.07%

8

0.82%

none ATC only (excl TCAM)

434

44.88%

133

13.75%

96

0.99%

53

5.48%

none excl. vits and TCAM

438

45.30%

475

49.10%

227

23.47%

73

7.55%

TCAM

0

0.00%

0

0.00%

220

22.75%

220

22.75%

A02

antacids

47

4.86%

0

0.00%

174

17.99%

204

21.10%

A03

anticholinergics (anti-emetics)

27

2.79%

1

0.10%

5

0.52%

33

3.41%

A06

laxatives

13

1.34%

12

1.24%

16

1.65%

39

4.03%

A07

anti-diarrhoeals

10

1.03%

2

0.21%

11

1.14%

18

1.86%

A10

diabetic treatment

13

1.34%

2

0.21%

4

0.41%

13

1.34%

A11

vitamins

179

18.51%

2

0.21%

71

7.34%

234

24.20%

A12

mineral supplements

3

0.31%

2

0.21%

10

1.03%

15

1.55%

B01

anti-thrombotic agents

1

0.10%

1

0.10%

0

0.00%

2

0.21%

B03

anti-anaemic

167

17.27%

815

84.28%

752

77.77%

935

96.69%

B05

plasma expanders

3

0.31%

0

0.00%

0

0.00%

3

0.31%

C01

cardiac therapy

2

0.21%

0

0.00%

0

0.00%

2

0.21%

C02

antihypertensives

20

2.07%

1

0.10%

4

0.41%

20

2.07%

C03

diuretics

16

1.65%

8

0.83%

8

0.83%

25

2.59%

C07

B blockers

1

0.10%

0

0.00%

0

0.00%

1

0.10%

C08

Ca channel blockers

8

0.83%

6

0.62%

1

0.10%

14

1.45%

C09

ACE-inhibitors

6

0.62%

1

0.10%

2

0.21%

8

0.83%

C10

lipid modifying agents

4

0.41%

1

0.10%

1

0.10%

5

0.52%

D01

topical antifungals

0

0.00%

0

0.00%

1

0.10%

1

0.10%

D02

emollients & protectants

37

3.83%

3

0.31%

25

2.59%

57

5.89%

D04

anti-pruritics

7

0.72%

0

0.00%

1

0.10%

8

0.83%

D06

topical antibiotics

4

0.41%

0

0.00%

2

0.21%

2

0.21%

D07

topical steroids

0

0.00%

2

0.21%

10

1.03%

26

2.69%

D08

antiseptics

0

0.00%

0

0.00%

1

0.10%

1

0.10%

G01

gynae topical anti-infectives

45

4.65%

7

0.72%

46

4.76%

88

9.10%

G02

other gynaecologicals

0

0.00%

0

0.00%

2

0.21%

2

0.21%

G03

sex hormones & contraceptives

8

0.83%

0

0.00%

14

1.45%

22

2.28%

G04

urologicals

6

0.62%

6

0.62%

14

1.45%

24

2.48%

H02

systemic steroids

9

0.93%

1

0.10%

2

0.21%

12

1.24%

H03

thyroid therapy

2

0.21%

0

0.00%

0

0.00%

2

0.21%

J01

systemic antibiotics

167

17.27%

55

5.69%

97

10.03%

258

26.68%

J02

systemic antimycotics

2

0.21%

0

0.00%

0

0.00%

1

0.10%

J04

Anti-mycobacterials

170

17.58%

5

0.52%

11

1.14%

175

18.10%

J05

antivirals

396

41.0%

284

29.4%

209

21.6%

450

46.5%

J07

vaccines

0

0.00%

225

23.27%

3

0.31%

226

23.37%

M01

NSAID & aspirin

37

3.83%

1

0.10%

41

4.24%

75

7.76%

N02

analgesics

190

19.65%

21

2.17%

505

52.22%

585

60.50%

N03

anti-epileptics

1

0.10%

1

0.10%

1

0.10%

2

0.21%

N05

psycholeptics

3

0.31%

0

0.00%

2

0.21%

4

0.41%

N06

anti-depressants

4

0.41%

1

0.10%

2

0.21%

7

0.72%

P01

anti-protozoals

36

3.70%

32

3.31%

71

7.3%

123

12.72%

P02

anthelmintics

3

0.31%

0

0.00%

0

0.00%

3

0.31%

P03

ectoparasites

13

1.34%

2

0.21%

6

0.62%

19

1.96%

R01

nasal preparations

5

0.52%

0

0.00%

37

3.83%

42

4.34%

R03

Drugs for obstructive airways disease

0

0.00%

7

0.72%

30

3.10%

38

3.93%

R05

cough preparations

0

0.00%

0

0.00%

40

4.14%

40

4.14%

R06

systemic antihistamines

54

5.58%

5

0.52%

80

8.27%

127

13.13%

S01

ophthalmologicals

4

0.41%

1

0.10%

1

0.10%

6

0.62%

S02

otologicals

1

0.10%

0

0.00%

0

0.00%

1

0.10%

  1. ACE Angiotensin-II converting enzyme, ACT Anatomical chemical therapeutic, NSAID Non-steroidal anti-inflammatory drugs, EDR Electronic dispensing record, TCAM Traditional, complementary, alternative medicines
  2. aThe master list comprised all three data sets combined: a medicine appeared only once per participant regardless of how many times it was reported during pregnancy or whether it was reported in one, two or all three datasets